Strikingly, a single dose of TCR-Ts co-expressing PD1-41BB and the PRAME-TCR was sufficient to clear tumors in vivo employing a mouse model in which transgenic TCR expression alone did not allow control of aggressive tumor growth. Here, PDCD1 is linked to neoplasm.